PMID- 21902635
OWN - NLM
STAT- MEDLINE
DCOM- 20120611
LR  - 20190918
IS  - 1873-4316 (Electronic)
IS  - 1389-2010 (Linking)
VI  - 12
IP  - 11
DP  - 2011 Nov
TI  - Stem cells in pharmaceutical biotechnology.
PG  - 1760-73
AB  - Multiple populations of stem cells have been indicated to potentially participate 
      in regeneration of injured organs. Especially, embryonic stem cells (ESC) and 
      recently inducible pluripotent stem cells (iPS) receive a marked attention from 
      scientists and clinicians for regenerative medicine because of their high 
      proliferative and differentiation capacities. Despite that ESC and iPS cells are 
      expected to give rise into multiple regenerative applications when their side 
      effects are overcame during appropriate preparation procedures, in fact their 
      most recent application of human ESC may, however, reside in their use as a tool 
      in drug development and disease modeling. This review focuses on the applications 
      of stem cells in pharmaceutical biotechnology. We discuss possible relevance of 
      pluripotent cell stem populations in developing physiological models for any 
      human tissue cell type useful for pharmacological, metabolic and toxicity 
      evaluation necessary in the earliest steps of drug development. The present 
      models applied for preclinical drug testing consist of primary cells or 
      immortalized cell lines that show limitations in terms of accessibility or 
      relevance to their in vivo counterparts. The availability of renewable human 
      cells with functional similarities to their in vivo counterparts is the first 
      landmark for a new generation of cell-based assays. We discuss the approaches for 
      using stem cells as valuable physiological targets of drug activity which may 
      increase the strength of target validation and efficacy potentially resulting in 
      introducing new safer remedies into clinical trials and the marketplace. 
      Moreover, we discuss the possible applications of stem cells for elucidating 
      mechanisms of disease pathogenesis. The knowledge about the mechanisms governing 
      the development and progression of multitude disorders which would come from the 
      cellular models established based on stem cells, may give rise to new 
      therapeutical strategies for such diseases. All together, the applications of 
      various cell types derived from patient specific pluripotent stem cells may lead 
      to targeted drug and cellular therapies for certain individuals.
FAU - Zuba-Surma, Ewa K
AU  - Zuba-Surma EK
AD  - Department of Medical Biotechnology, Biophysics and Biotechnology, Jagiellonian 
      University, Krakow, Poland. ewa.zuba-surma@uj.edu.pl
FAU - Jozkowicz, Alicja
AU  - Jozkowicz A
FAU - Dulak, Jozef
AU  - Dulak J
LA  - eng
GR  - Wellcome Trust/United Kingdom
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - Netherlands
TA  - Curr Pharm Biotechnol
JT  - Current pharmaceutical biotechnology
JID - 100960530
RN  - 0 (Pharmaceutical Preparations)
SB  - IM
MH  - Animals
MH  - *Biotechnology/methods
MH  - *Cell Differentiation/drug effects/genetics
MH  - Disease Models, Animal
MH  - Drug Delivery Systems
MH  - Drug Evaluation, Preclinical/methods
MH  - Drug-Related Side Effects and Adverse Reactions
MH  - Humans
MH  - Models, Biological
MH  - Pharmaceutical Preparations/administration & dosage
MH  - Regenerative Medicine
MH  - Stem Cell Transplantation
MH  - *Stem Cells/cytology/drug effects/metabolism
MH  - *Technology, Pharmaceutical/methods
EDAT- 2011/09/10 06:00
MHDA- 2012/06/12 06:00
CRDT- 2011/09/10 06:00
PHST- 2010/02/24 00:00 [received]
PHST- 2010/04/15 00:00 [accepted]
PHST- 2011/09/10 06:00 [entrez]
PHST- 2011/09/10 06:00 [pubmed]
PHST- 2012/06/12 06:00 [medline]
AID - BSP/CPB/E-Pub/000268-12-12 [pii]
AID - 10.2174/138920111798377120 [doi]
PST - ppublish
SO  - Curr Pharm Biotechnol. 2011 Nov;12(11):1760-73. doi: 10.2174/138920111798377120.